title: Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
abstract: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. The absence of expression and/or amplification of estrogen and progesterone receptor as well as ERBB-2 prevent the use of currently available endocrine options and/or ERBB-2-directed drugs and indicates chemotherapy as the main current therapy. TNBC represents approximately 15% of breast cancer cases with high index of heterogeneity. Here, we review the role of androgen receptor in breast carcinogenesis and its association with alterations in the expression pattern and functional roles of regulatory molecules and signal transduction pathways in TNBC. Additionally, based on the so far preclinical and clinical published data, we evaluate the perspectives for using and/or developing androgen receptor targeting strategies for specific TNBC subtypes.
authors.affiliation: Molecular Oncology Unit, Department of Biological Chemistry, University of Athens Medical School, 75 M. Asias Street, 11527 Athens, Greece. Electronic address: arisanestis@gmail.com.
authors.forename: Aristomenis
authors.initials: A
authors.lastname: Anestis
authors.affiliation: Molecular Oncology Unit, Department of Biological Chemistry, University of Athens Medical School, 75 M. Asias Street, 11527 Athens, Greece. Electronic address: mkaramouz@med.uoa.gr.
authors.forename: Michalis V
authors.initials: MV
authors.lastname: Karamouzis
authors.affiliation: Molecular Oncology Unit, Department of Biological Chemistry, University of Athens Medical School, 75 M. Asias Street, 11527 Athens, Greece. Electronic address: gdalagior@med.uoa.gr.
authors.forename: Georgia
authors.initials: G
authors.lastname: Dalagiorgou
authors.affiliation: Molecular Oncology Unit, Department of Biological Chemistry, University of Athens Medical School, 75 M. Asias Street, 11527 Athens, Greece. Electronic address: papavas@med.uoa.gr.
authors.forename: Athanasios G
authors.initials: AG
authors.lastname: Papavassiliou
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011944:Receptors, Androgen / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000209:etiology
chemical_list: C410798:AR protein, human; D000726:Androgen Antagonists; D011944:Receptors, Androgen
keywords: Androgen receptor; Breast cancer; Estrogen receptor; Triple negative